GetPeptide Protocol
Abstract
GetPeptide is a decentralized research organization (DRO) dedicated to funding, owning, and accelerating peptide therapeutics. Through an onchain treasury, IP-NFTs, and a curated network of research partners, GetPeptide routes capital directly to high-leverage peptide science — bypassing the funding bottlenecks that currently strand promising candidates between discovery and clinic.
1. The Peptide Era
Peptides — short chains of amino acids, typically between two and fifty residues — are among the body's primary signaling molecules. Hormones, neuromodulators, growth factors, immune effectors, and antimicrobial agents are all, to a significant degree, peptides.
For decades, peptides were considered impractical as drugs. That assumption has collapsed. Advances in solid-phase synthesis, rational peptide engineering (PEGylation, lipidation, cyclization, non-natural amino acids), and delivery science have transformed peptides into one of the most clinically successful drug modalities of the modern era.
GLP-1 receptor agonists have reshaped global metabolic health. Antimicrobial peptides are entering trials against multidrug-resistant pathogens. Senolytic and signaling peptides are defining the early clinical frontier of longevity medicine.
2. The Bottleneck
Despite this acceleration, peptide research remains structurally underfunded. Grant cycles are slow — a promising candidate may wait two to three years for funding decisions. Pharma economics are exclusionary — tens of thousands of plausible peptide candidates are abandoned not because they fail science, but because they fail business cases. IP is captured. Patients carry the cost.
These are coordination failures, not scientific ones.
3. Our Thesis
We believe peptide research is one of the highest-leverage opportunities in decentralized science. The molecules are well-characterized. Synthesis costs continue to fall. The clinical pipeline is global. What is missing is a coordination layer — a way to pool capital, allocate it through expert review, hold the resulting IP collectively, and redistribute proceeds transparently.
GetPeptide is that coordination layer.
4. System Overview
The Treasury — an onchain pool of capital, denominated in stablecoins and $PEPL, used to fund approved research proposals and operate the protocol.
The Scientific Council — a standing body of credentialed peptide researchers and clinicians who triage incoming proposals, conduct technical review, and produce funding recommendations to the DAO.
The DAO — $PEPL token holders, who ratify funding allocations, approve research partnerships, and govern protocol parameters.
The IP-NFT Layer — each funded research project produces an IP-NFT representing the underlying intellectual property, custodied by the DAO and licensed under terms designed to maximize both translational impact and treasury return.
5. Revenue Model
Revenue flows from IP licensing. When a funded research project produces commercially viable intellectual property, the DAO licenses it to pharmaceutical partners, biotech startups, or clinical-stage companies. Licensing fees flow back to the treasury, funding the next cycle of research.
Contributors who participated in the funding of a specific project receive a proportional share of licensing revenue through the IP-NFT mechanism.
6. What's Next
GetPeptide is currently in Phase 2 — Token & Treasury. $PEPL token launch, DAO governance deployment, and treasury seeding are underway. The first research proposals will be funded in Q4 2026.
Follow @Get_Peptide on X for updates.